lundi 30 mars 2020


IMPLANET: Completion of the First JAZZ Band Surgical Procedure in Brazil, Latin America’s Largest Market

Par Rédaction , dans Communiqués , le 29 janvier 2016

Thursday, January 28th 2016 at 5:00pm UTC

BORDEAUX, France & BOSTON–(BUSINESS WIRE)– Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible),
a medical technology company specializing in vertebral and knee-surgery
implants, announces that the first idiopathic scoliosis surgical
procedure using the JAZZ platform in Brazil has been successfully
carried out by Dr. Raphael Pratali and his team at the Hospital do
Servidor Público Estadual in São Paulo. Further surgical procedures are
already scheduled in Brazil.

JAZZ technology is an excellent alternative to screws in maximizing
the correction of major spine deformities. Using JAZZ implants in a
hybrid construct in idiopathic scoliosis surgery makes it possible to
restore the patient’s sagittal balance. By significantly reducing
operating time, we provide the patient with additional safety. I will
obviously be using JAZZ technology during my surgical procedures from
now on,
” says Dr Pratali.

Alvaro Tadeus, CEO of Importek, Implanet’s commercial partner in Brazil,
adds: “We are delighted by the unanimous consensus regarding this
first surgical procedure, which was carried out by an eminent spine
surgeon in Brazil. We will now be able to accelerate the marketing of
JAZZ technology in this country, backed by our in-depth knowledge of the
spine market, our network of influential opinion leaders and our
specific sales structure
.”

Ludovic Lastennet, CEO of Implanet, concludes: “We are impressed by
how quickly the first JAZZ surgery was performed following the
regulatory approval received two months ago from the Brazilian health
authorities. I am pleased to hear that Dr. Pratali and his team are
delighted with the advantages our technology has provided. This will no
doubt enable its adoption to spread among peers in this market, which
saw close to 27,000 vertebral fusion surgeries in 2015.

Next financial press release: 2015 annual results, on 30 March
2016 (after market).

About IMPLANET
Founded in 2007, IMPLANET is a medical
technology company that manufactures high-quality implants for
orthopedic surgery. Its flagship product, the JAZZ latest-generation
implant, aims to treat spinal pathologies requiring vertebral fusion
surgery. Protected by four families of international patents, JAZZ has
obtained 510(k) regulatory clearance from the Food and Drug
Administration (FDA) in the United States and the CE mark. IMPLANET
employs 45 staff and recorded 2015 sales of €6.7 million. For further
information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in
Boston in 2013.
IMPLANET is listed on Compartment C of the
Euronext™ regulated market in Paris.

Contacts

IMPLANET
Ludovic Lastennet, Tel. : +33 (0)5 57 99 55 55
CEO
investors@implanet.com
or
NewCap
Investor
Relations
Florent Alba, Tel. : +33 (0)1 44 71 94 94
implanet@newcap.eu
or
NewCap
Media
Relations
Nicolas Merigeau, Tel. : +33 (0)1 44 71 94 98
implanet@newcap.eu

Source: IMPLANET

Étiquettes : , , , , , , , , , , ,